Crown Bioscience Signals verhoogde investeringen in digitale transformatie met benoeming van nieuwe COO
SAN DIEGO– (BUSINESS WIRE) – Crown Bioscience kondigt vandaag de benoeming aan van John Gu als Chief Operations Officer. Mr. Gu zal leidinggeven bij het bevorderen van excellentie in de wereldwijde activiteiten van CrownBio, waarbij hij zijn diepgaande expertise in digitalisering zal gebruiken om de productiviteit te verhogen.
De heer Gu komt bij CrownBio van WuXi Nextcode, een wereldleider op het gebied van genomische data-analyse, waar hij zowel algemeen manager was voor de Chinese activiteiten als Chief Digital Officer. Bij WuXi Nextcode leidde John een blockchain-geactiveerde veilige mobiele gezondheidsdatabank die genomische, klinische en gedragsgegevens integreert voor precieze gezondheidszorg. Hij leidde ook de inspanning om big data- en AI-technologieën toe te passen om de nauwkeurigheid en efficiëntie van medische genomische interpretaties te verbeteren en de klantervaring via digitale technologieën te verbeteren.
Crown Bioscience Signals Increased Investment in Digital Transformation with Appointment of New COO
SAN DIEGO–(BUSINESS WIRE)– Crown Bioscience today announces the appointment of John Gu as chief operations officer. Mr. Gu will provide leadership in promoting excellence across CrownBio’s global operations, leveraging his deep expertise in digitalization to drive productivity.
Crown Bioscience Chief Operations Officer John Gu (Photo: Business Wire)
Mr. Gu joins CrownBio from WuXi Nextcode, a global leader in genomic data analysis, where he was general manager for the China business, as well as chief digital officer. At WuXi Nextcode, John spearheaded a block-chain enabled secure mobile health data bank integrating genomic, clinical and behavioral data for precision healthcare. He also led the effort to apply big data and AI technologies to improve medical genomic interpretation accuracy and efficiency and to improve customer experience via digital technologies.
“I am thrilled to welcome John to the leadership team,” said Armin Spura, PhD, chief executive officer of CrownBio. “John brings a wealth of experience in global business and operational transformation, and his deep expertise in the growth of technology platforms will be instrumental in helping CrownBio’s global operations evolve and excel, and at the same time develop our innovative digital and in silico preclinical solutions.”
Prior to WuXi Nextcode, Mr. Gu held successive senior technology and operations roles across digital and technology companies, where he successfully led multiple large-scale global IT transformation projects. This includes Alcatel-Lucent, where John led the IT integration and digital transformation across operations in over 140 countries.
“I am delighted to join CrownBio at this point in time,” said John Gu. “Life science is experiencing exponential growth due to recent developments in science and technologies across multiple disciplines. Through enhanced operational excellence, innovation, and digital technologies, we are well poised to continue to deliver value to our customers.”
Mr. Gu holds an MBA from the University of Chicago, an MS in Computer Science from Loyola University of Chicago, and a double-major BS in Computer Science and Electrical Engineering from Shanghai Jiao Tong University.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
● https://www.crownbio.com
● https://www.jsrlifesciences.com
Contacts
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.